Epoetin alfa - medicine shortage information

Back to ALL shortages and discontinuations    Back to CRITICAL shortages and discontinuations

If you are having difficulty obtaining a medicine that has been prescribed to you, talk to your doctor or pharmacist to discuss suitable options to continue your care.

More information about medicine shortages and how to access alternative medicines is available at the Medicine Shortages hub

Product details Supply Impact Dates Further Details
EPREX epoetin alfa (rch) 20000IU/0.5mL injection syringe
AUST R: 73486
Active ingredients:
Epoetin alfa

Dosage form:
Injection, solution

Sponsor:
Janssen-Cilag Pty Ltd

Phone:
1800226334

Deletion from market:
30 Sep 2026

Shortage status:
To be discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Commercial Changes / Commercial viability

Management action:
The sponsor will continue to supply until the market deletion date.
Patients are advised to consult their health professional to discuss alternative treatment options.
EPREX epoetin alfa (rch) 30000IU/0.75mL injection syringe
AUST R: 135069
Active ingredients:
Epoetin alfa

Dosage form:
Injection, solution

Sponsor:
Janssen-Cilag Pty Ltd

Phone:
1800226334

Deletion from market:
30 Sep 2026

Shortage status:
To be discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Commercial Changes / Commercial viability

Management action:
The sponsor will continue to supply until the market deletion date.
Patients are advised to consult their health professional to discuss alternative treatment options.
EPREX epoetin alfa (rch) 40000IU/mL injection syringe
AUST R: 73487
Active ingredients:
Epoetin alfa

Dosage form:
Injection, solution

Sponsor:
Janssen-Cilag Pty Ltd

Phone:
1800226334

Deletion from market:
30 Sep 2026

Shortage status:
To be discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Commercial Changes / Commercial viability

Management action:
The sponsor will continue to supply until the market deletion date.
Patients are advised to consult their health professional to discuss alternative treatment options.
EPREX epoetin alfa (rch) 5000IU/0.5mL injection syringe
AUST R: 76970
Active ingredients:
Epoetin alfa

Dosage form:
Injection, solution

Sponsor:
Janssen-Cilag Pty Ltd

Phone:
1800226334

Deletion from market:
30 Sep 2026

Shortage status:
To be discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Commercial Changes / Commercial viability

Management action:
The sponsor will continue to supply until the market deletion date.
Patients are advised to consult their health professional to discuss alternative treatment options.
EPREX epoetin alfa (rch) 6000IU/0.6mL injection syringe
AUST R: 76971
Active ingredients:
Epoetin alfa

Dosage form:
Injection, solution

Sponsor:
Janssen-Cilag Pty Ltd

Phone:
1800226334

Deletion from market:
30 Sep 2026

Shortage status:
To be discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Commercial Changes / Commercial viability

Management action:
The sponsor will continue to supply until the market deletion date.
Patients are advised to consult their health professional to discuss alternative treatment options.
EPREX epoetin alfa (rch) 8000IU/0.8mL injection syringe
AUST R: 76973
Active ingredients:
Epoetin alfa

Dosage form:
Injection, solution

Sponsor:
Janssen-Cilag Pty Ltd

Phone:
1800226334

Deletion from market:
30 Sep 2026

Shortage status:
To be discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Commercial Changes / Commercial viability

Management action:
The sponsor will continue to supply until the market deletion date.
Patients are advised to consult their health professional to discuss alternative treatment options.
EPREX epoetin alfa 10000IU/1.0mL injection syringe
AUST R: 65446
Active ingredients:
Epoetin alfa

Dosage form:
Injection, solution

Sponsor:
Janssen-Cilag Pty Ltd

Phone:
1800226334

Deletion from market:
30 Sep 2026

Shortage status:
To be discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Commercial Changes / Commercial viability

Management action:
The sponsor will continue to supply until the market deletion date.
Patients are advised to consult their health professional to discuss alternative treatment options.
EPREX epoetin alfa 1000IU/0.5mL injection syringe
AUST R: 65442
Active ingredients:
Epoetin alfa

Dosage form:
Injection, solution

Sponsor:
Janssen-Cilag Pty Ltd

Phone:
1800226334

Deletion from market:
30 Sep 2026

Shortage status:
To be discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Commercial Changes / Commercial viability

Management action:
The sponsor will continue to supply until the market deletion date.
Patients are advised to consult their health professional to discuss alternative treatment options.
EPREX epoetin alfa 2000IU/0.5mL injection syringe
AUST R: 65443
Active ingredients:
Epoetin alfa

Dosage form:
Injection, solution

Sponsor:
Janssen-Cilag Pty Ltd

Phone:
1800226334

Deletion from market:
30 Sep 2026

Shortage status:
To be discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Commercial Changes / Commercial viability

Management action:
The sponsor will continue to supply until the market deletion date.
Patients are advised to consult their health professional to discuss alternative treatment options.
EPREX epoetin alfa 3000IU/0.3mL injection syringe
AUST R: 65444
Active ingredients:
Epoetin alfa

Dosage form:
Injection, solution

Sponsor:
Janssen-Cilag Pty Ltd

Phone:
1800226334

Deletion from market:
30 Sep 2026

Shortage status:
To be discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Commercial Changes / Commercial viability

Management action:
The sponsor will continue to supply until the market deletion date.
Patients are advised to consult their health professional to discuss alternative treatment options.
EPREX epoetin alfa 4000IU/0.4mL injection syringe
AUST R: 65445
Active ingredients:
Epoetin alfa

Dosage form:
Injection, solution

Sponsor:
Janssen-Cilag Pty Ltd

Phone:
1800226334

Deletion from market:
30 Sep 2026

Shortage status:
To be discontinued

Availability:
Reduction in supply until supply is exhausted

Reason:
Commercial Changes / Commercial viability

Management action:
The sponsor will continue to supply until the market deletion date.
Patients are advised to consult their health professional to discuss alternative treatment options.